COVID-19 Testing Data licensing agreement

Diaceutics PLC

(“Diaceutics” or “the Company” or “the Group”) 

COVID-19 Testing Data licensing agreement 

Contract to provide data insights with global pharmaceutical company 

Diaceutics PLC, (AIM: DXRX), announces that it has secured a data licensing agreement with a global pharmaceutical company to provide COVID-19 testing data insights in the US enabled by DXRX - the Company’s proprietary diagnostic network for precision medicine. With circa 400 COVID-19 treatments[1] now in development to address the global pandemic, this contract win, which is the result of insights made available by the Company’s recent algorithmic development of a COVID-19 diagnostic disease pathway (DDP®)[2], highlights that the Group is in a position to address the imminent opportunity presented by the COVID-19 treatment market using its DXRX data solution capabilities.

The details of the contract, including the identity of the pharmaceutical company and the value, are confidential and no further information can be disclosed. The contract value does not change management's expectations of performance for the current financial year.

Diaceutics’ DXRX platform provides unrivalled access to deep data insights and analysis from 49 Diagnostic Deductive Pathways®, enabling the Company to help pharmaceutical customers understand the testing journey for patients across multiple disease types and identify real word data trends around COVID-19 testing.

Commenting, Peter Keeling, Diaceutics’ Chief Executive Officer said: “We are delighted to be able to facilitate access to this valuable COVID-tested patient cohort. This first COVID-19 data-licensing agreement for the Company provides testing data insights and analytics to pharmaceutical companies actively developing treatments for the disease. With hundreds of COVID-19 treatments now in development to address a pandemic at global scale, it is critically important that pharmaceutical companies lean in towards digital testing solutions such as those enabled by DXRX, to ensure that they have the data insights, and testing infrastructure required to get patients tested and treated.”


 [1] https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus/pipeline-tracker

 [2] Diaceutics has established many years of proprietary data which has been used to develop data algorithms informing the testing pathway, creating a deep disease-level understanding which the Company describes as a Diagnostic Deductive Pathway® (DDP)

Enquiries

Diaceutics PLC

Peter Keeling, Chief Executive Officer

Philip White, Chief Financial Officer

 
Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny

Michael Johnson (Sales)

+44 (0)207 397 8900

Walbrook PR

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893